Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

PARPs (Poly(ADP-Ribose) Polymerases) Inhibitors & Pancreatic Ductal Adenocarcinoma (PDAC) / Pancreatic Cancer (BRCA m)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

The benefit of PARP inhibitors for patients with Pancreatic Ductal Adenocarcinoma (PDAC) / Pancreatic Cancer (BRCA m) has been very modest.
Alkassis et al. 2021 Expert Opin.Ther.Targ. 25: 547-557

…

A new targeted treatment for patients with a germline BRCA mutation: olaparib in pancreatic cancer
Verdaguer et al. 2020 Future Oncology 16: 2691–2700
BRCA mutations in pancreatic cancer and progress in their targeting
Alkassis et al. 2021 Expert Opin.Ther.Targ. 25: 547-557
Review

7/1/2026